)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
NeuroScientific Biopharmaceuticals
NeuroScientific Biopharmaceuticals (NSB) investor relations material
NeuroScientific Biopharmaceuticals Investor presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor presentation summary4 Nov, 2026
Corporate and capital snapshot
As at November 2026: share price A$0.05; market capitalisation ~A$19.5m; cash ~A$3.9m at 30 September 2026.
Capital structure: 389.72m ordinary shares, 1.50m performance shares and 43.25m options.
Market opportunity and positioning
Global Crohn’s disease market cited at US$13B+; 6–8m patients globally, with 30% not responding to standard therapies.
StemSmart targets patients who have failed at least two mechanisms, positioning it as a new therapy line after biologic failure.
Fistulising disease can cause severe complications, and surgery may become inevitable when treatment options are limited.
StemSmart technology and clinical evidence
Purpose-built mesenchymal stem cell therapy for severe inflammation; proprietary activation process, patented technology and production under TGA accreditation.
Open-label Phase 2 luminal study in 18 anti-TNF-refractory patients reported 78% clinical response, 44% remission and 44% endoscopic improvement at Day 42.
Crohn’s Special Access results in fistulising patients reported an 80% response rate in five adults; CDAI, PDAI and IBDQ improved in all five, with MRI trending toward fistula healing.
Prior studies reported no serious adverse events attributed to MSCs; the Phase 2 study was single-arm and had no placebo control.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from NeuroScientific Biopharmaceuticals
- FDA feedback cleared key trial questions as StemSmart Phase 2 preparation advanced.NSB
Q1 2027 TU - Net loss widened to $4.7M as R&D spending rose, despite a 279% income increase from incentives.NSBH2 2026
- StemSmart showed 80% efficacy in Crohn's Disease, with strong cash reserves and Phase 2 trials planned.NSBQ4 2026 TU
- StemSmart showed strong efficacy in Crohn's, with two phase II trials set to start by year-end.NSBStatus update
- StemSmart shows strong early efficacy in Crohn's, with Phase 2 trials and scale-up on track.NSBQ3 2026 TU
- StemSmart™ delivers promising clinical results for refractory Crohn's, advancing to Phase 2 trials.NSBInvestor presentation
- Returned to profitability in FY2024 with $324,210 net profit and strong cash reserves for R&D.NSBH2 2024
- Net loss widened to $1.7M as R&D accelerated, with cash reserves supporting continued development.NSBH1 2026
- StemSmart™ MSC platform shows strong clinical promise and is advancing toward global Phase 2 trials.NSBCompany presentation
NeuroScientific Biopharmaceuticals
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
NeuroScientific Biopharmaceuticals Limited is a biotechnology company focused on researching and developing therapies for neurodegenerative diseases and neurotrauma. The company’s work centers on novel peptide-based treatments aimed at conditions such as Alzheimer’s disease, multiple sclerosis, and other neurological disorders that involve degeneration or damage to nerve cells. The company is headquartered in Perth, Australia, and its shares are listed on the ASX.